characteristics and impact of drug detailing for gabapentin特点及影响药物加巴喷丁的详细.pdfVIP

PLoS MEDICINE Characteristics and Impact of Drug Detailing for Gabapentin Michael A. Steinman1,2*, G. Michael Harper1,2, Mary-Margaret Chren1,3, C. Seth Landefeld1,2, Lisa A. Bero4,5 1 San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America, 2 Division of Geriatrics, University of California, San Francisco, California, United States of America, 3 Department of Dermatology, University of California, San Francisco, California, United States of America, 4 Department of Clinical Pharmacy, University of California, San Francisco, California, United States of America, 5 Institute for Health Policy Studies, University of California, San Francisco, California, United States of America Funding: This work was supported A B S T R A C T by a Veterans Affairs Health Services Research Development Research Career Development Award (MAS); Background by grants from the National Institute on Arthritis and Musculoskeletal and Skin Disease (K24 AR052667) (MMC), Sales visits by pharmaceutical representatives (‘‘drug detailing’’) are common, but little is the National Institute on Aging known about the content of these visits or about the impact of visit characteristics on (AG00912) and the John A. Hartford prescribing behavior. In this study, we evaluated the content and impact of detail visits for Foundation (2003–0244) (CSL), and the California Tobacco-Related gabapentin by analyzing market research forms completed by physicians after receiving a Disease Research Programs (13RT- detail visit for this drug. 0108) (LAB); and by the Health Services Research Enhancement Award Program (REAP) at the San Metho